In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please amend pending claims 35 and 36 as noted below.

1-13. (Canceled)

14. (Previously Presented) A pharmaceutical preparation comprising

a CFTR expression regulator, wherein the CFTR expression regulator is a polysaccharide that is an LPS core moiety comprising



wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;
wherein Y is selected from the group consisting of rhamnose and H; and
wherein Z is selected from the group consisting of glucose and H; and

a pharmaceutically acceptable carrier.

15. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises



16. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises



17. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises



18. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises



19. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises



20. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises



21. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.

22. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is sterile.

23. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is formulated in a unit dosage in an amount effective for treating *Pseudomonal* infection.

24. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is formulated as an aerosol for inhalation.

25. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is formulated as an injectable preparation.

26. (Previously Presented) A composition of matter comprising

a covalent conjugate of a non-toxic lipid and a polysaccharide comprising



wherein X is selected from the group consisting of glucose, glucose-rhamnose and H; Y is selected from the group consisting of rhamnose and H; and Z is selected from the group consisting of glucose and H.

27. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises



28. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises



29. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises



30. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises



31. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises



32. (Previously Presented) The composition of matter of claim 26 wherein the polysaccharide comprises





33. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.

34. (Previously Presented) The composition of matter of claim 26 wherein the lipid has the following structural formula: $CH_3(CH_2)_nCOOH$ wherein n=1-50.

35. (Currently amended) The composition of matter of claim 34 ~~wherein the lipid~~ wherein the lipid is in the wall of a liposome containing a bioactive agent, wherein the bioactive agent is selected from the group consisting of a diagnostic molecule, a molecule affecting metabolism of a cell, an anti-microbial molecule and a therapeutic molecule.

36. (Currently amended) A composition of matter comprising

a covalent conjugate of a bioactive agent wherein the bioactive agent is selected from the group consisting of a diagnostic molecule, a molecule affecting metabolism of a cell, an anti-microbial molecule and a therapeutic molecule, and a polysaccharide comprising



wherein X is selected from the group consisting of glucose, glucose-rhamnose and H; Y is selected from the group consisting of rhamnose and H; and Z is selected from the group consisting of glucose and H.

37. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises



38. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises



39. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises



40. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises



41. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises



42. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises



43. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.

44-68. (Canceled)